Ahon Pharmaceutical Co., Ltd.

Quick facts

Phase 3 pipeline

• ET-26 · Diabetes
  ET-26 is a small molecule that targets the SGLT2 receptor.
• FCN-437c,Fulvestrant,Goserelin acetate · Oncology
  This combination therapy uses an estrogen receptor degrader (fulvestrant) and a gonadotropin-releasing hormone agonist (goserelin) to suppress estrogen signaling in hormone receptor-positive breast cancer.
• Placebo,Fulvestrant,Goserelin acetate · Oncology
  This combination uses fulvestrant to block estrogen receptors in cancer cells and goserelin to suppress ovarian hormone production, while placebo serves as a control arm.

Phase 1 pipeline

• ET-26HCl
• FCN-411 Dose-escalation
• FCN-411 Dose-expansion
• FCN-437c
• Methoxyethyl Etomidate Hydrochloride

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ahon Pharmaceutical Co., Ltd. portfolio CI brief
• Ahon Pharmaceutical Co., Ltd. pipeline updates RSS